Medexus resubmits NDA as it still looks to repurpose a decades-old drug
The German drugmaker medac’s US subsidiary is hoping the second time is the charm for the company, as it is officially asking the FDA once …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
